Press & News

ViewReleaseInStandardHtml

New CEO and Group President at Boule Diagnostics

Ernst Westman is resigning as CEO and Group President of Boule Diagnostics at the end of first quarter 2017. The board has named Fredrik Dalborg as new CEO and Group President effective 3 April.

“After 23 years as CEO and good growth for Boule, I am handing the company reins to a new force. It has been incredibly exciting and challenging to build Boule up into the internationally successful and growth oriented company it is today. The company is now in a position that provides a platform for continued vigorous growth with good profitability. With his expertise and experience, Dalborg is an excellent choice to lead Boule forwards in this work,” Westman says.

Dalborg, 44 years old, joins Boule from Terumo BCT where he was Vice President with global responsibility for the performance of the Therapeutic Systems business area (with a turnover of around 180 mUSD). Over the course of his successful career, Dalborg has spent some 14 years working in the global market for medical technology and been based in the USA, Belgium and Singapore. In addition to excellent knowledge of Boule's prioritized markets, the USA and emerging countries, Dalborg is highly experienced in developing growth companies with good profitability.

“Dalborg's leadership, strong drive, global experience and complementary international contact network will be an important asset in the further development of an already strong Boule”, Chairman of the Board Peter Ehrenheim says.

The Board has recommended the nomination committee propose Westman as a board member at the AGM on 11 May.

For more information, please contact:

Peter Ehrenheim, Chairman of the Board Boule Diagnostics AB, tel +46 706-67 57 11
Ernst Westman, VD och koncernchef, Boule Diagnostics AB, tel +46 708-60 88 63

 

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary hematology. The group is comprised of operating subsidiaries in Sweden, the US and China. The Boule Diagnostics share is traded on NASDAQ Nordic since 2011. www.boule.se

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET January 10, 2016.